![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
The PD-1/PD-L1 axis is characterized as an important checkpoint of immune activation, particularly through negatively regulating T cell function. Although accumulated evidence has demonstrated the patients with some types of tumor benefit from blockade of PD-1/PD-L1 signaling pathway, the possible synergistic effect of combination of radiotherapy and anti-PD-1/PD-L1 antibody still need to be explored. Here, we report a case of patient who was diagnosed with metastatic mediastinal leiomyosarcoma and treated by combination of local radiotherapy and anti-PD-1 antibody nivolumab. Remarkable tumor regression was observed at both the irradiated focus and distant metastatic sites 2 months later after combined treatment. The patient has tumor mutational burden (8.7 somatic mutations/Mb) and positive PD-L1 expression. The increased circulating lymphocytes suggest induced activation of immune response after combination treatment. Free disease progression has reached one and a half years as far.
Abbreviations
| PD-1 | = | programmed death-1 |
| PD-L1 | = | programmed death ligand-1 |
| NSCLC | = | non-small cell lung cancer |
| CT | = | computed tomography |
| WES | = | whole exome sequencing; |
| ALC | = | absolute lymphocyte count |
| LYM% | = | lymphocyte percentage |
| ICD | = | induce immunogenic cell death |
| TMB | = | tumor mutational burden. |
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Ethics statment
All work was approved by the Medical Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and complied strictly with national ethical guidelines.